The Epstein-Barr virus (EBV) transforms B cells in part by inhibiting the cellular apoptotic programme. This is also observed when Burkitt lymphoma cell lines are infected with EBV. Induction of apoptosis is one of the mechanisms by which¯udarabine inhibits the growth of cells with low proliferative capacity. This compound can also inhibit several other mechanisms in the cell, including inhibition of the synthesis of factors such as STAT1. To analyse the relationship between EBV status,¯udarabine-induced apoptosis, and transcription factors we studied the EBV-negative Burkitt lymphoma cell line BL2, its EBV-infected counterpart BL2.B95.8 and the EBV-transformed cell line PRI. The BL2 cell line was found to be very sensitive to¯udarabine. The BL2.B95.8 and PRI cells were both resistant but the latter to a lesser extent. In the PRI cells¯udarabine activated p53, but not in the BL2.B95.8 cells in which the p53 pathway is inactivated. We observed that this inactivation results in part from the lack of expression of the MDM2 inhibitor p14ARF. Conversely, there was a substantial constitutive activation of STAT1, and not of the other STATs, in the BL2.B95.8 cells and a modest one in the PRI cells. Furthermore, expression of STAT1 was signi®cantly reduced by¯udarabine treatment in the PRI cells, but not in the BL2.BL95.8 cells. Finally, the expression of p21WAF1/CIP1 was detected only in the BL2.B95.8 and PRI cells. This protein, known to play a role in cell survival, may therefore be involved in the resistance of the BL2.B95.8 cells to¯udarabine.
Introduction
The Epstein Barr virus (EBV) can induce the proliferation of resting B cells in vitro. The immortalized lymphoblastoid cell lines so obtained express the full range of the viral proteins including the nuclear antigens EBNA-1, -2, -3A, -3B and -3C and EBNA-LP and the membrane proteins LMP1, LMP2A and LMP2B. The growth of the lymphoblastoid cell lines is due to a continuous induction of cell division and to an inhibition of the apoptotic programme. The eect of EBV upon cell survival is also observable in Burkitt's lymphoma cell lines: when these cells are infected with EBV they are converted to a type III latency whereby they express the full range of the viral proteins and are consequently protected from apoptosis (Henderson et al., 1991) . In the Burkitt's lymphoma cell lines c-myc deregulation is thought to play a major role in tumorigenicity (Magrath, 1990) . In these cells, predisposition to c-myc-induced apoptosis is counteracted by EBV infection which up-regulates bcl-2 expression (Ruf et al., 1999) . Interestingly, inhibition of NF-kB in a lymphoblastoid cell line abrogated the expression of bcl-2 and promoted apoptosis (Feuillard et al., 2000) . Such an inhibition of apoptosis can also be observed by transfection of individual EBV proteins. For instance, Fas-mediated apoptosis was found to be inhibited in the MCF cells by the lytic-cycle protein BHFR1, which is homologous to the anti-apoptotic protein bcl-2 (Foghsgaard and Jaattela, 1997) . However, the expression of the EBV proteins per se may be insucient to protect the cells against apoptosis. For instance, the BJAB cells expressing BHFR1 are not protected against serum starvation-mediated apoptosis (Foghsgaard and Jaattela, 1997) . Conversely some EBV-positive cells that do not express either LMP1 or BHFR1 are resistant to apoptosis (Ruf et al., 1999) . Thus, the EBV infection of the B cells inhibits apoptosis by mechanisms that are not fully understood.
Fludarabine is an adenosine nucleoside analogue that has been extensively used to treat haematological malignancies (Ross et al., 1993) . Although it was shown to inhibit DNA synthesis,¯udarabine can also inhibit RNA synthesis, methylation, DNA repair and nicotinamide adenine metabolism. Furthermore,¯udar-abine was found to be ecient in the treatment of chronic lymphoid leukaemia with low proliferative capacity, suggesting that it may also trigger apoptosis. In fact,¯udarabine induces the expression of the proapoptotic protein p53 (Chernova et al., 1995) , and cells carrying an inactivating mutation of p53 have been reported to be resistant to¯udarabine (Pettitt et al., 1999; Thomas et al., 1996) . Another possible target for¯udarabine is STAT1, a transcription factor that is involved in cellular responses to interferon (IFN). STAT1 is primarily involved in the slower growth of cells in response to IFN, its role is most clearly demonstrated in STAT17/7 animals which have an increased development of tumours in response to carcinogens, and, in this context the suppression of the expression of p53 enhanced the spontaneous formation of tumours (reviewed in Bromberg and Darnell, 2000) . Interestingly, STAT1 which is activated in several EBV-positive Burkitt lymphoma and lymphoblastoid lines Weber-Nordt et al., 1996) was found to be speci®cally inhibited by¯udarabine in the peripheral blood mononuclear cells (Frank et al., 1999) .
In this study we wished to determine whether a B cell line obtained by transformation by EBV and a Burkitt cell line infected by EBV, responded in a similar manner to¯udarabine, and what molecular mechanisms could account for the dierences observed. For this purpose, three dierent types of cell lines were used: the EBV-infected Burkitt lymphoma line (BL2.B95.8), its non-infected counterpart BL2 and the EBV-immortalized lymphoblastoid cell line PRI. The induction of apoptosis in these cell lines showed that the two EBV positive lines were resistant tō udarabine and that the BL2 cell line was very sensitive. However, there was a notable dierence between the two EBV-positive cell lines, namely, the BL2.B95.8 cells showed much higher resistance tō udarabine than the PRI cells. Analysis of the mechanisms underlying these dierences showed that apart from an impaired p53 pathway, the BL2.B95.8 cells displayed a strong STAT1 activation. Conversely, in the PRI cells, which express wild-type p53, the activation of STAT1 was much less pronounced. Furthermore, the expression of p21WAF1/CIP1, previously found to play a critical role in the survival of some cell lines (Lawlor and Rotwein, 2000) was found to be high in the¯udarabine resistant cell lines.
Results
Resistance to fludarabine induced apoptosis in the BL2.B95.8 cell line
Under normal conditions of culture, the BL2 cells underwent spontaneous apoptosis; this was less pronounced in the BL2.B95.8 and PRI cells ( Figure   1a ). The BL2 cells were all killed within 48 h by 50 mM udarabine while the BL2.B95.8 cells were resistant ( Figure 1a) . The PRI cells, although much more resistant than the BL2 cells, were still noticeably sensitive to¯udarabine (Figure 1a ). The analysis of the cells by¯ow cytometry showed that after udarabine treatment (48 h), 98% of the BL2, 71% of the PRI and 41% of the BL2.B95.8 cells were undergoing apoptosis (Figure 1b) . The cell cycle was arrested by¯udarabine in all the three cell lines (not shown) suggesting that the dierential response tō udarabine treatment most likely results from dierences in the apoptotic responses. To analyse the mechanisms involved in this dierential resistance the expression of several factors involved in the regulation of apoptosis were compared in the three cell lines BL2, BL2.B95.8 and PRI.
Fludarabine modifies the expression of proapoptotic proteins differently in the BL2.B95.8 and PRI cells
The expression of bcl-2 and bax was previously shown to correlate with the sensitivity of the B-CLL cells tō udarabine (Thomas et al., 1996) . In addition, the exposure of the CLL cells to¯udarabine was found to down-regulate the expression of bcl-2 (Petersen et al., 1996) . Finally, EBV is known to induce the expression of bcl-2. Therefore, the expression of bcl-2 and of factors involved in the regulation of apoptosis was analysed in the BL2, BL2.B95.8 and PRI cells. The Western blots showed increased expression of bcl-2 in the BL2.B95.8 and PRI cells as compared to the BL2 cells (Figure 2 ). The antiapoptotic protein bcl-XL was expressed at similar levels in the BL2 and BL2.B95.8, and less in the PRI cells (Figure 2 ). The expression of the proapoptotic bcl-2-antagonist bax was higher in the BL2.B95.8 than in the PRI cells, and undetectable in the BL2 cells (Figure 2 ). After treatment with udarabine, the expression of bcl2 and bcl-XL was unchanged in the BL2.B95.8 and PRI cells (Figure 3a , upper band). There was little change in the expression of bax in the BL2.B95.8 (Figure 3a) , but in the PRI cells its expression was increased (Figure 3a, lane 4) . Thus, following¯udarabine treatment there was a reduction of the anti-versus pro-apoptotic proteins ratio, which was more pronounced in the PRI than in the BL2.B95.8 cells.
Fludarabine activates the DNA binding of p53 in the PRI cells, not in the BL2.B95.8 cells
The expression of the apoptosis regulatory protein p53 was examined. In both the PRI and the BL2 cell lines, p53 is in a non-mutated, active, form (Capoulade et al., 1998) . Its expression as determined by Western blotting was much higher in the BL2.B95.8 than in the BL2 cells, while its level in the PRI cells was intermediate ( Figure 2 ). Anticancer drugs such as¯udarabine are known to increase the activity of p53 (Fisher, 1994; Lowe et al., 1994) . The DNA binding activity of p53 was examined in the ¯udarabine treated cells. In the nuclear extracts from untreated BL2.B95.8 and PRI cells, the DNA binding to the p53 speci®c probe was undetectable ( Figure  3b , lanes 1 and 3). After¯udarabine treatment there was a strong binding with the PRI cell extracts ( Figure 3b , lane 4) and a weak binding with the BL2.B95.8 cell extracts ( Figure 3b , lane 2). Thus, the p53 response is impaired in the BL2.B95.8 cells, but not in the PRI cells. The expression of MDM2 was detected in all the three cell lines (not shown). p14ARF is a tumour suppressor (Kamijo et al., 1997) which can activate p53 through its ability to associate with MDM2 and promote its localization to the nucleolus (Stott et al., 1998) . Analysis by RT ± PCR showed that p14ARF was expressed in the DG75 and the HeLa cell lines, but not in the Jurkat cell line (Figure 3c ). Similarly, it is only expressed in the PRI cells, but not in the BL2 and BL2.B95.8 cells ( Figure  3c ). The lack of expression of p14ARF in the BL2 and BL2.B95.8 cells provides an explanation for the fact that although expressed in its wild type form, p53 is inactive in these cells. The expression of the cell cycle inhibitor p21WAF1/CIP1 was found to be tightly linked to dierentiation in myoblasts (Lawlor and Rotwein, 2000) and shown to prevent apoptosis in macrophages (Xaus et al., 1999) . p21WAF1/CIP1 was ®rst described as an p53-induced gene (el-Deiry et al., 1993) . Indeed, in the PRI cells, in which the p53 activity is increased by¯udarabine, we detected by semi quantitative PCR an increased expression of p21WAF1/CIP1 ( STAT1 is constitutively activated in the BL2.B95.8 and PRI cells, but its expression is inhibited by fludarabine only in the PRI cells As expected, since both cell lines are EBV-positive, the NF-kB activity determined by EMSA in both the BL2.B95.8 and PRI cells was high in contrast with the BL2 cells in which it was very low (Figure 4d ).
Since activation of the STATs was described in lymphoblastoid cell lines and in cells transfected with LMP1 (Gires et al., 1999) we analysed their expression and activation in all the three cell lines. The results showed a much higher expression of STAT1 in the BL2.B95.8 and PRI cells than in the BL2 cells (Figure 4a ), while the expression of the other STATs was unchanged (not shown). The phosphorylation of STAT1 on tyrosine 701 and serine 727 has been previously shown to correlate with its activation. STAT1 phosphorylation on tyrosine 701 was detected in the BL2.B95.8 and PRI cells, but not in the BL2 cells (Figure 4a ). Phosphorylation on serine 727 was high in both the BL2.B95.8 and PRI cells, and low in the BL2 cells (Figure 4a ). The activation of STAT1 in nuclear extracts from the BL2.B95.8 and PRI cells was detected by gel retardation (Figure 4b,c) . No activation was observed in the BL2 cells ( Figure  4b , lane 1). A supershift with a speci®c antibody demonstrated that only STAT1 was activated in the BL2.B95.8 cells (Figure 4a, lane 3) . Thus in both the BL2.B95.8 and PRI cells the activation of STAT1 is observed. However, a stronger activation can be seen in the BL2.B95.8 cells. The p53-induced cell cycle inhibitor p21WAF1/CIP1 has been previously found to be induced by STAT1 (Chin et al., 1996) . Indeed, analysis of its expression by Western blotting showed that p21WAF1/CIP1 is undetectable in the BL2 cells and expressed in the BL2.B95.8 and PRI cells ( Figure  4e ). Fludarabine has previously been found to selectively inhibit the expression of STAT1 in peripheral blood mononuclear cells (PBMC) (Frank et al., 1999) . It was therefore of interest to analyse the eect of¯udarabine on STAT1 in the BL2.B95.8 and PRI 
Discussion
In this paper, we ®nd that the induction of apoptosis by¯udarabine is dierent in three cell lines, which dier in their EBV status. The EBV-negative Burkitt lymphoma cell line BL2 is very sensitive to¯udarabine while the two EBV-positive cell lines BL2.B95.8 and PRI are resistant. Interestingly however, the two EBVpositive cell lines respond dierently to¯udarabine. The EBV-immortalized lymphoblastoid cell line PRI is more sensitive than the EBV-infected Burkitt lymphoma cell line BL2.B95.8. Fludarabine is a widely studied anticancer agent, which can eciently kill slowly dividing cells by inducing apoptosis. One mechanism involves alterations in the expression levels of pro-or anti-apoptotic proteins of the bcl-2 family (Kaufmann and Earnshaw, 2000; Korsmeyer, 1992) . Indeed, the anti-apoptotic protein bcl-2 was shown to be induced by EBV in B cells (Henderson et al., 1991; Rowe et al., 1994) , and its down-regulation was shown to be associated with apoptosis (Feuillard et al., 2000) . However, the sensitivity to¯udarabine of cells from chronic lymphoid leukaemia was found to be either related (Petersen et al., 1996) or not (Consoli et al., 1998) to the inhibition of the expression of bcl-2. Furthermore, in some lymphoblastoid cell lines the induction of apoptosis following NF-kB inhibition occurred in the presence of high levels of bcl-2 (Cahir-McFarland et al., 2000) . In this study, we ®nd that the expression levels of bcl-2 are not strikingly dierent in the three cell lines studied and do not vary following¯udarabine treatment, the bcl-2 related antiapoptotic protein bcl-XL, on the other hand, is somewhat less expressed in the PRI cell line. The survival or death response of cells to apoptotic stimuli was also shown to depend on proapoptotic bcl-2 family proteins such as bax (Chao and Korsmeyer, 1998) . Speci®cally, a pre-set ratio of bcl-2/bax was shown to be critical for cell death or survival (Korsmeyer et al., 1993) . In this work, we ®nd that the expression of bax is somewhat higher in the PRI cells and increases following treatment with¯udarabine. These changes may contribute to the sensitivity of the PRI cells tō udarabine, yet, overall, in the cell systems we used there seems to be little correlation of the expression levels of pro-or anti-apoptotic proteins, to the sensitivity of the cells to¯udarabine. Yet, proteins of the bcl-2 family were shown to be regulated by posttranscriptional mechanisms such as phosphorylation (Chao and Korsmeyer, 1998) . Our experiments do not eliminate the possibility that changes in the phosphorylation of these eectors are brought about bȳ udarabine. Another pivotal regulator of apoptosis is the tumour suppressor p53. Although wild-type p53 is expressed in the BL2 and BL2.B95.8 cells (Capoulade et al., 1998) and result not shown), we detected almost no activation of this eector in these two cell lines. This contrasted with the strong activation we observed in the PRI cells. The low activity of p53 is related to an over-expression of MDM2 (Capoulade et al., 1998) , an inhibitor of p53 (Momand et al., 2000) . The MDM2 protein is itself inhibited by p14ARF, which activates p53 by relocating MDM2 to the nucleolus (Weber et al., 2000) . The ®nding that p14ARF is not expressed in both the BL2 and BL2.B95.8 cells thus suggests that in addition to an MDM2 over-expression, the absence of p14ARF contributes to the inactivation of p53 in these cells. The apoptosis triggered in the BL2 and BL2.B95.8 cells by¯udarabine is therefore p53-independent. This is in agreement with previous observations in the B cells from chronic lymphoid leukaemia patients showing that¯udarabine toxicity depends mostly on p53-independent mechanisms (Thomas et al., 1996) . The strong activation of STAT1 constitutes a notable dierence between the BL2 and the BL2.B95.8 cells. Activation of STAT1, which is known to result from interferon triggering of cells, was demonstrated in a B cell line transfected with the EBV protein LMP1 (Gires et al., 1999) . In this study, the detection of the activation of STAT1 in the BL2.B95.8 cells, which express LMP1 (not shown), but not in the BL2 cells, further demonstrates the relationship between the activation of STAT1 and LMP1. The activation of STAT1 is also detected in the PRI cells, however the activation is much stronger in the BL2.B95.8 cells, despite the fact that the phosphorylation levels of STAT1 on tyrosine 701 and serine 727 are similar in both cell lines. Another notable dierence between the PRI and the BL2.B95.8 cell lines is that upon treatment with¯udarabine, the expression of STAT1 decreases in the PRI cells, but not in the BL2.B95.8 cells. This eect was speci®c of STAT1 and was not observed with STAT5 nor STAT3, in agreement with previous ®ndings on peripheral blood mononuclear cells (Frank et al., 1999) . Inhibition of the expression of STAT1 following¯udarabine treatment was also detected in the BL2 cells, and in another Burkitt lymphoma cell line (BL41) but not in its EBVinfected counterpart BL41.B95.8 (not shown). The mechanism by which the speci®c inhibition of STAT1 expression occurs is not known. Inhibition of DNA and RNA synthesis by¯udarabine is documented but mRNA translation may also be aected. STAT1 signalling may partially overlap that of p53 as loss of STAT1 was shown to further enhance oncogenesis in p53-null mice (Kaplan et al., 1998) . In fact, both STAT1 and p53 have common targets, such as p21WAF1/CIP1 (Chin et al., 1996) . Indeed, in the BL2.B95.8 cells STAT1 may be involved in the regulation of the expression of p21WAF1/CIP1. The demonstration that in myoblasts p21WAF1/CIP1 is a critical factor of survival (Lawlor and Rotwein, 2000) suggests that in the BL2.B95.8 cells this induction may play a role in their resistance to¯udarabine. The mechanism by which¯udarabine treatment further stimulates the expression of p21WAF1/CIP1 is not understood. Interestingly, although they do not resist to¯udarabine-induced apoptosis as eciently as the BL2.B95.8 cells, the PRI cells still have an elevated level of expression of p21WAF1/CIP1. Thus the overexpression of p21WAF1/CIP1 may not be sucient to protect these cells or may have other unknown functions.
Thus, in the BL2.B95.8 cells the combination of p53 inactivation and STAT1 constitutive activation may be responsible for the particularly ecient resistance to¯udarabine-induced apoptosis. In the PRI cells, the lower resistance to¯udarabine is associated with an active p53 and a reduced level of STAT1 activation. These two events may be sucient to explain the higher sensitivity of the PRI cells tō udarabine.
Materials and methods

Cell culture and treatments
The lymphoblastoid cell line PRI and the Burkitt lymphoma cell line BL2 and its EBV infected counterpart (infected with B 95.8) BL2.B95.8 were cultured in RPMI 1640 medium supplemented with penicillin, streptomycin, glutamine and 10% foetal calf serum and maintained in a 5% CO 2 incubator at 378C. The cells were routinely diluted to 1 : 4 with fresh medium. Where speci®ed,¯udarabine (Schering Plough) was extemporaneously diluted in water and added to 50 mM for 48 to 72 h.
Western-blot analysis
The cells were washed twice in phosphate buered saline (PBS) counted and lysed by resuspension in 26SDS sample buer (Biorad) followed by 10 s of sonication to break the DNA. The samples were separated on SDS-polyacrylamide gels (7, 10 and 15%) and transferred onto nitro-cellulose membranes (Schleicher and Schuell). Following transfer, the membranes were stained in Ponceau Red to verify that equal amounts of protein were loaded. The membranes were then washed in water for 30 min and incubated overnight at 48C in tris-buered saline (tris 10 mM pH 8, NaCl 30 mM, TBS) supplemented with dried skimmed milk (3%). Speci®c antibodies were added for 2 h. After three washes of 30 min each with TBS, the secondary antibodies conjugated with horseradish peroxidase (1 : 5000 in TBS) were added for 1 h, followed by another three washes of 30 min in TBS. Bands were visualized on Xomat R ®lms (Kodak) by enhanced chemiluminescence following the supplier's procedure (New England Biolabs). Antibodies to the following proteins were used: STAT1, STAT3, STAT5a, STAT5b phospho (tyrosine 701)-STAT1 and phospho (serine 727)-STAT1 (New-England Biolabs), p53 (UBI), p21WAF1/CIP1 (Santa-Cruz), MDM2 (Pharmingen), bcl-2 (Dako), bcl-XL (Santa-Cruz) and bax (Pharmingen).
FACS analysis
For the analysis of the cell population distribution,¯uores-cence-activated cell sorting (FACS) was used. Annexin V-FITC labelling: the cells ( 10 5 ) were rapidly washed twice in PBS and resuspended in 100 ml of a buer containing HEPES 10 mM pH: 7.4, NaCl: 140 mM, CaCl2: 2.5 mM, and incubated with 5 ml of FITC-annexin V (Pharmingen) and 10 mM propidium iodide (Sigma) for 15 min in the dark at room temperature. The cells were then diluted to 1 : 5 with the HEPES buer and analysed. The counting of cells was set at 10 000 events.
RNA expression
Total RNA was extracted from 10 7 cells and used as a template for the cDNA synthesis. The PCR ampli®cation (35 cycles) of transcripts encoding p14ARF was performed with the following primers: sense: GGGTTTTCGTGGTTCA-CATC and antisense: ACCAGCGTGTCCAGGAAG and the ampli®cation of the transcripts encoding glyceraldehyde phosphate dehydrogenase performed with the primers: sense: GAGTCAACGGATTTGGTCGT and antisense: TGTGG-TCATGAGTCCTTCCA. RT-PCR products were detected by direct ethidium bromide staining after electrophoretic separation on agarose gels. The PCR ampli®cation of p21WAF1/CIP1 for the semi quantitative PCR analysis was performed with 25 cycles and the following primers: sense: GGAAGACCATGTGGACCTGT, antisense: CCCAGCAC-TCTTAGGAACCTC.
Electrophoretic migration shift assay (EMSA)
To prepare the nuclear extracts, the cells were rapidly washed twice in PBS and lysed (10 8 cells/ml) in buer A (HEPES: 20 mM pH 7.9, glycerol: 10%, KCl: 10 mM, EDTA: 1 mM, NP-40: 0.2%, phenylmethylsulphonyl¯uor-ide: 1 mM, aprotinin: 10 mg/ml, leupeptin: 10 mg/ml, vanadate: 1 mM and DTT: 1 mM). After a 5 min lysis at 48C, the extracts were centrifuged at 12 000 g for 2 min at 48C. The supernatants were collected and the pellets were gently resuspended (2610 8 cells/ml) in buer A to which NaCl was added to 0.35 M. After 30 min at 48C with occasional shaking the extracts were centrifuged at 20 000 g for 5 min at 48C. The supernatants were collected, frozen in liquid nitrogen and stored at 7808C. The protein concentrations were measured using the Bradford procedure (Biorad). The DNA-binding reaction mixture contained: 2 mg poly (dI-dC), 2 ml nuclear lysate (10 mg of protein), 1 ml (5610 4 c.p.m.) 32 P-labelled probe (the SIE sequence for STATs was: 5'-CATTTCCCGTAAATC-3', the p53 binding site from the p21WAF1 promoter region was: 5'-GAACATGTCCCAACATGTT, and the NF-kB binding site was: 5'-GCCATGGGGGGATCCCCGAAGTCC-3'). The reaction was performed in a ®nal volume of 20 ml in a buer containing HEPES: 10 mM pH 8, EDTA: 100 mM, NaCl: 50 mM, KCl: 50 mM, MgCl 2 : 5 mM, spermidine: 4 mM, DTT: 2 mM, bovine serum albumin: 0.1 mg/ml, glycerol: 2.5% and ®coll: 4%. After labelling with the T4 polynucleotide kinase (Roche) and g-32 P-ATP, the oligonucleotide was separated on a 10% polyacrylamide gel, and eluted in 50 mM KCl. The binding reaction mixtures were incubated at 48C for 30 min. The samples were analysed on a 5% nondenaturing acrylamide gel run at 200 V for 3 h. The gels were dried and exposed to an X-ray ®lm overnight at room temperature.
